États-Unis · Bourse & Finance · Yahoo Finance

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

Publié par Yahoo Finance · États-Unis il y a 10 h

AnnJi Pharmaceutical Co., Ltd. (AnnJi, TPEx: 7754), a clinical-stage drug development company focused on innovative small molecules, today announced that it is proceeding with the…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

À lire aussi

Japan’s PMI data signals cooling momentum across manufacturing and services

Joint venture of OKX and NYSE parent ICE files for 24/7 tokenized U.S. stock trading

Russia hospitalizes almost 200 people after researcher's death from plague: reports

After 11 years on an H-1B visa, I still miss my family back home. Here’s why I stay in the US.

Zcash activates NU7 on testnet ahead of November mainnet target

Sam Altman says 'the world should accept some bad things happening for the benefits' of AI

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

Partager

À lire aussi

Japan’s PMI data signals cooling momentum across manufacturing and services

Joint venture of OKX and NYSE parent ICE files for 24/7 tokenized U.S. stock trading

Russia hospitalizes almost 200 people after researcher's death from plague: reports

After 11 years on an H-1B visa, I still miss my family back home. Here’s why I stay in the US.

Zcash activates NU7 on testnet ahead of November mainnet target

Sam Altman says 'the world should accept some bad things happening for the benefits' of AI